private equity firms who own 35% along with institutions invested in Trevi Therapeutics, Inc. (NASDAQ:TRVI) saw increase in their holdings value last week [Yahoo! Finance]
Trevi Therapeutics, Inc. (TRVI)
Company Research
Source: Yahoo! Finance
The top 5 shareholders own 51% of the company 34% of Trevi Therapeutics is held by Institutions To get a sense of who is truly in control of Trevi Therapeutics, Inc. ( NASDAQ:TRVI ), it is important to understand the ownership structure of the business. We can see that private equity firms own the lion's share in the company with 35% ownership. Put another way, the group faces the maximum upside potential (or downside risk). Following a 11% increase in the stock price last week, private equity firms profited the most, but institutions who own 34% stock also stood to gain from the increase. In the chart below, we zoom in on the different ownership groups of Trevi Therapeutics. Check out our latest analysis for Trevi Therapeutics What Does The Institutional Ownership Tell Us About Trevi Therapeutics? Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major in
Show less
Read more
Impact Snapshot
Event Time:
TRVI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRVI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRVI alerts
High impacting Trevi Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TRVI
News
- Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024 [Yahoo! Finance]Yahoo! Finance
- Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024PR Newswire
- Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.MarketBeat
- Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference [Yahoo! Finance]Yahoo! Finance
- Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International ConferencePR Newswire
TRVI
Earnings
- 3/20/24 - Beat
TRVI
Sec Filings
- 4/29/24 - Form ARS
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- TRVI's page on the SEC website